Personalized Disease Management
We understand that every patient is unique and individualized treatment is often necessary. We strive to help physicians improve patient outcome through personalized therapy. Our passion is slowing and ultimately preventing the progression of autoimmune diseases and its associated disabilities.

To address this need, Glycominds offers diagnostic and prognostic tests that give physicians additional information to guide treatment decisions for patients with Multiple Sclerosis and Crohn's Disease.
News & Events
New Release!
Newly published article in the American Gastroenterology Journal Regarding Glycominds' novel serological markers for Crohn's Disease>>


New MS Article in Press
New Article In Press: in Journal Neuroimmunol a new USA and German study again shows that neurological patients positive for the anti-GAGA4 biomarker are most likely MS patients>>


New CD Article in Press
New Article In Press: in the Journal of Inflamm Bowel Disease regarding prognostic data with the IBDX serological markers for Crohn's Disease>>.


A New Way to Identify Patients
Likely to have Multiple Sclerosis
www.gms.net
Individualized Risk Assessment
of Complicated Crohn's Patients
www.ibdx.net
contact us | site map
© 2009 Glycominds Ltd. All Right Reserved